Bioreactor Startup Comes Together Using Soviet Technology And U.S. Financing

In an unprecedented deal, RiboGene Inc. is putting a Soviet team's advanced research into production with American money MENLO PARK, Calif.A year and a half ago, venture capitalist Petri Vainio was considering buying into a proposal from protein chemist and would-be entrepreneur Kin-Ping Wong. So Vainio began an investigation commonly performed by patent attorneys to see whether any other inventor, anywhere in the world, had come up with a similar idea. Vainio discovered that a group of Sovie

Written byTa Heppenheimer
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share


In an unprecedented deal, RiboGene Inc. is putting a Soviet team's advanced research into production with American money
MENLO PARK, Calif.A year and a half ago, venture capitalist Petri Vainio was considering buying into a proposal from protein chemist and would-be entrepreneur Kin-Ping Wong. So Vainio began an investigation commonly performed by patent attorneys to see whether any other inventor, anywhere in the world, had come up with a similar idea.

Vainio discovered that a group of Soviet scientists not only was working on the very same project, but also was way ahead of Wong. Rather than dump Wong's plan, deal-maker Vainio incorporated both their talents, and after a year of intercontinental negotiations, he and Wong announced a collaboration unprecedented in the annals of biotechnology startups: a company built upon money and management from the United States, but using Soviet technology. RiboGene Inc., incorporated in May, began with the idea ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies